CTE Sessions at EANM’14

EANM’14 – Mini Course 2

October 19, 2014, 15:45 – 16:45
Updates in Conventional Radiopharmaceuticals for Diagnosis or Radiotherapy

Chairpersons: M. Hinterreiter (Linz), R. Kaboteh (Gothenburg)


Speakers
extended
abstract
P. Kolenc Peitl (Ljubljana):
Quo Vadis, Conventional Radiopharmaceutical for Diagnosis?
S. Ezziddin (Homburg):
Quo Vadis, Conventional Radiopharmaceutical for Radionuclide Therapy?


Educational Objectives:

  1. Overview of the advancement of the conventional radiopharmaceuticals which are actually used for diagnosis and/or therapy
  2. Show the differences between the new conventional radiopharmaceuticals and those ones which have been used up to now (e.g. concerning the pharmacodynamics)
  3. Learn about the advantages and/or about the disadvantages in relation to those radiopharmaceuticals which have been used up to now (e.g. concerning the side effects)
  4. Highlight the main aspects of radiation protection for the patient and the staff concerning the application of these new conventional radiopharmaceuticals
  5. Show the procedure for determining the quality of these new radiopharmaceuticals and describe the criteria for a good quality
  6. Give an overview about the future in relation to the development of new radiopharmaceuticals for diagnosis and/or therapy


Summary:

Nuclear Medicine is a medical discipline which underlies a permanent advancement. On the one hand this progress is caused by new imaging modalities like SPECT/CT. On the other hand there is as well a development of new radiopharmaceuticals for diagnosis and/or radionuclide therapy. Especially in the field of radionuclide therapy, some completely new radiopharmaceuticals were researched in the last few years and are available now; in the field of the conventional imaging nuclear medicine a progress in relation to the development of new radiopharmaceuticals is going on. All this research causes a broader spectrum of available radiopharmaceuticals for therapy and/or diagnosis which allows to cover more clinical indications and to answer more clinical questions.

This session highlights this advancement and wants to give an overview about the status quo in relation to these fields of radiopharmaceuticals. Concerning the application of these radiopharmaceuticals, radiation protection for both staff and the patients, and the criteria for a good quality are also explored in this session. A focus is also given to the future, more precisely to the need of new radiopharmaceuticals and the present state-of-science to meet clinical demand.


Key Words:

Advancement, Advantages, Disadvantages, Side Effects, Radiation Protection, Quality, Future

Back to top